Concepedia

Takuji Sato

TS

Statistics

Publications

6

Citations

303

H-Index

6

Active since

1978

Affiliations

Dana-Farber Cancer Institute(Current)

Translational Genomics Research Institute

Harvard University

Takuji Sato is an author at Dana-Farber Cancer Institute specializing in tumor biology, apoptosis, and cancer biology.

Top concepts

Publications per year

1978–2022

6

Publications

6

CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity

Keiichi Sakakibara, Naoya Saito, Takuji Sato et al. · Blood · 2011 · 116 citations

Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System

Chigusa Morizane, Nozomu Machida, Yoshitaka Honma et al. · JAMA Oncology · 2022 · 85 citations · Full text

Cell cycle phenotype-based optimization of G2-abrogating peptides yields CBP501 with a unique mechanism of action at the G2 checkpoint

Shi-Ken Sha, Takuji Sato, Hidetaka Kobayashi et al. · Molecular Cancer Therapeutics · 2007 · 50 citations · Full text

CBS9106-Induced CRM1 Degradation Is Mediated by Cullin Ring Ligase Activity and the Neddylation Pathway

Naoya Saito, Keiichi Sakakibara, Takuji Sato et al. · Molecular Cancer Therapeutics · 2014 · 27 citations

, , +16

CBP501 induces immunogenic tumor cell death and CD8 T cell infiltration into tumors in combination with platinum, and increases the efficacy of immune checkpoint inhibitors against tumors in mice

Keiichi Sakakibara, Takuji Sato, Donald Küfe et al. · Oncotarget · 2017 · 15 citations · Full text

1–5 of 6